nach oben

Erschienen in:

20.01.2017 | Original Article

The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices

verfasst von: Teresa M. Salgado, Emily Mackler, Jane A. Severson, Jamie Lindsay, Peter Batra, Laura Petersen, Karen B. Farris

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The Michigan Oncology Quality Consortium (MOQC) is a continuous quality improvement collaborative seeking to improve oncology care in Michigan, including for patients taking oral chemotherapy. The aim of this study was to assess the relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics to inform future oncology care.

Methods

A multicenter cross-sectional observational study was conducted using an online survey to examine patient activation (patient activation measure, PAM), health literacy, symptom burden (Edmonton Symptom Assessment System, ESAS), confidence to self-manage side effects (fatigue, nausea, and diarrhea), and adherence to oral oncolytics. Inclusion criteria were patients taking an oral oncolytic for at least 1 month. Bivariate analyses and logistic regression were performed to evaluate relationships between the variables.

Results

A total of 125 respondents, mean (SD) age 66.2 (13.6), 57.7% female, and 95.1% Caucasian completed the survey. The mean (SD) PAM score was 65.0 (18.0). Confidence to manage fatigue, nausea, and diarrhea was associated with higher activation, and confidence to self-manage fatigue and diarrhea were associated with higher health literacy. About 30% of participants reported some level of non-adherence to oral oncolytics, and those who experienced side effects (Fisher’s exact test p = 0.033) and with shorter length of therapy (t test p = 0.027) were significantly more likely to be non-adherent.

Conclusions

These findings show that there is room for improvement across practices involved with MOQC with regard to supporting patients taking oral oncolytics. Patients will need to improve their activation levels, and oncology clinics will need to create new workflows in order to enhance self-care management ability for patients taking oral oncolytics.

Bedell CH (2003) A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs 7:5–9CrossRefPubMed

Khandelwal N, Duncan I, Ahmed T, Rubinstein E, Pegus C (2011) Impact of clinical oral chemotherapy program on wastage and hospitalizations. Am J Manag Care 17:e169–e173PubMed

Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, Langbaum TS, Leedy RD, Muller RJ, Newcomer LN, O'Brien S, Reinke D, Rubino M, Saltz L, Walters RS (2008) NCCN task force report: oral chemotherapy. J Natl Compr Cancer Netw 6(Suppl 3):S1–14

Schwartz RN, Eng KJ, Frieze DA, Gosselin TK, Griffith N, Seung AH, Hinkel JM, Johnson PE, Johnson SA, Li EC, Szabatura AH, Wong MK (2010) NCCN task force report: specialty pharmacy. J Natl Compr Cancer Netw 8(Suppl 4):S1–12

Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, Patel RA, Schwartz R, Tames MJ, Terkola R, Vadnais B, Wright D, Meier K (2011) Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Pract 7:7–12CrossRefPubMedPubMedCentral

Zerillo JA, Pham TH, Kadlubek P, Severson JA, Mackler E, Jacobson JO, Blayney DW (2015) Administration of oral chemotherapy: results from three rounds of the quality oncology practice initiative. J Oncol Pract 11:e255–e262CrossRefPubMed

Kidd LA (2014) Consequences, control and appraisal: cues and barriers to engaging in self-management among people affected by colorectal cancer—a secondary analysis of qualitative data. Health Expect 17:565–578CrossRefPubMed

Greene J, Hibbard JH (2012) Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med 27:520–526CrossRefPubMed

Kinney RL, Lemon SC, Person SD, Pagoto SL, Saczynski JS (2015) The association between patient activation and medication adherence, hospitalization, and emergency room utilization in patients with chronic illnesses: a systematic review. Patient Educ Couns 98:545–552CrossRefPubMed

10.

Mosen DM, Schmittdiel J, Hibbard J, Sobel D, Remmers C, Bellows J (2007) Is patient activation associated with outcomes of care for adults with chronic conditions? J Ambul Care Manage 30:21–29CrossRefPubMed

11.

Katz ML, Fisher JL, Fleming K, Paskett ED (2012) Patient activation increases colorectal cancer screening rates: a randomized trial among low-income minority patients. Cancer Epidemiol Biomark Prev 21:45–52CrossRef

12.

Foulon V, Schoffski P, Wolter P (2011) Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg 66:85–96PubMed

13.

Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691–705CrossRefPubMedPubMedCentral

14.

Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56–66CrossRefPubMed

15.

Huang WC, Chen CY, Lin SJ, Chang CS (2016) Medication adherence to oral anticancer drugs: systematic review. Expert Rev Anticancer Ther 16:423–432CrossRefPubMed

16.

Greer JA, Amoyal N, Nisotel L, Fishbein JN, MacDonald J, Stagl J, Lennes I, Temel JS, Safren SA, Pirl WF (2016) A systematic review of adherence to oral antineoplastic therapies. Oncologist 21:354–376CrossRefPubMedPubMedCentral

17.

McCue DA, Lohr LK, Pick AM (2014) Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy 34:481–494CrossRefPubMed

18.

Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381–2388CrossRefPubMed

19.

Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529–537CrossRefPubMed

20.

Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. PharmacoEconomics 25:481–496CrossRefPubMed

21.

Roop JC, Wu HS (2014) Current practice patterns for oral chemotherapy: results of a national survey. Oncol Nurs Forum 41:185–194CrossRefPubMed

22.

Bourmaud A, Pacaut C, Melis A, Tinquaut F, Magne N, Merrouche Y, Chauvin F (2014) Is oral chemotherapy prescription safe for patients? A cross-sectional survey. Ann Oncol 25:500–504CrossRefPubMed

23.

Weingart SN, Flug J, Brouillard D, Morway L, Partridge A, Bartel S, Shulman LN, Connor M (2007) Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ 334:407CrossRefPubMedPubMedCentral

24.

Hibbard JH, Mahoney ER, Stockard J, Tusler M (2005) Development and testing of a short form of the patient activation measure. Health Serv Res 40:1918–1930CrossRefPubMedPubMedCentral

25.

Hibbard JH, Stockard J, Mahoney ER, Tusler M (2004) Development of the patient activation measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res 39:1005–1026CrossRefPubMedPubMedCentral

26.

Watanabe SM, Nekolaichuk CL, Beaumont C (2012) The Edmonton Symptom Assessment System, a proposed tool for distress screening in cancer patients: development and refinement. Psychooncology 21:977–985CrossRefPubMed

27.

Severson JA, Mackler E, Marini B, Blayney DW (2014) Association of high symptom burden with oral oncolytic agents. J Clin Oncol 32:(suppl 31; abstr 177)

28.

Feldman BJ, Fredericksen RJ, Crane PK, Safren SA, Mugavero MJ, Willig JH, Simoni JM, Wilson IB, Saag MS, Kitahata MM, Crane HM (2013) Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav 17:307–318CrossRefPubMedPubMedCentral

29.

Lu M, Safren SA, Skolnik PR, Rogers WH, Coady W, Hardy H, Wilson IB (2008) Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav 12:86–94CrossRefPubMed

30.

Unni EJ, Farris KB (2015) Development of a new scale to measure self-reported medication nonadherence. Res Social Adm Pharm 11:e133–e143CrossRefPubMed

31.

Peterson PN, Shetterly SM, Clarke CL, Bekelman DB, Chan PS, Allen LA, Matlock DD, Magid DJ, Masoudi FA (2011) Health literacy and outcomes among patients with heart failure. JAMA 305:1695–1701CrossRefPubMedPubMedCentral

32.

Chew LD, Bradley KA, Boyko EJ (2004) Brief questions to identify patients with inadequate health literacy. Fam Med 36:588–594PubMed

33.

DeSalvo KB, Fisher WP, Tran K, Bloser N, Merrill W, Peabody J (2006) Assessing measurement properties of two single-item general health measures. Qual Life Res 15:191–201CrossRefPubMed

34.

Bassan F, Peter F, Houbre B, Brennstuhl MJ, Costantini M, Speyer E, Tarquinio C (2014) Adherence to oral antineoplastic agents by cancer patients: definition and literature review. Eur J Cancer Care (Engl) 23:22–35CrossRef

35.

Mathes T, Pieper D, Antoine SL, Eikermann M (2014) Adherence influencing factors in patients taking oral anticancer agents: a systematic review. Cancer Epidemiol 38:214–226CrossRefPubMed

36.

Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Van Hecke A (2013) Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev 39:610–621CrossRefPubMed

37.

Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, Martiat P, Mineur P, Van Eygen K, MacDonald K, De Geest S, Albrecht T, Abraham I (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:5401–5411CrossRefPubMed

38.

Marques P, Pierin A (2008) Factors that affect cancer patient compliance to oral antineoplastic therapy. Acta Paul Enferm 21:323–329CrossRef

39.

Hendriks M, Rademakers J (2014) Relationships between patient activation, disease-specific knowledge and health outcomes among people with diabetes; a survey study. BMC Health Serv Res 14:393CrossRefPubMedPubMedCentral

40.

Sheikh S, Hendry P, Kalynych C, Owensby B, Johnson J, Kraemer DF, Carden D (2016) Assessing patient activation and health literacy in the ED. Am J Emerg Med 34:93–96CrossRefPubMed

41.

Smith SG, Curtis LM, Wardle J, von Wagner C, Wolf MS (2013) Skill set or mind set? Associations between health literacy, patient activation and health. PLoS One 8:e74373CrossRefPubMedPubMedCentral

42.

Eichler C, Pia M, Sibylle M, Sauerwald A, Friedrich W, Warm M (2015) Cognitive behavioral therapy in breast cancer patients—a feasibility study of an 8 week intervention for tumor associated fatigue treatment. Asian Pac J Cancer Prev 16:1063–1067CrossRefPubMed

43.

Berry DL, Blumenstein BA, Halpenny B, Wolpin S, Fann JR, Austin-Seymour M, Bush N, Karras BT, Lober WB, McCorkle R (2011) Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial. J Clin Oncol 29:1029–1035CrossRefPubMedPubMedCentral

44.

Spoelstra SL, Given BA, Given CW, Grant M, Sikorskii A, You M, Decker V (2013) An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: an exploratory study. Cancer Nurs 36:18–28CrossRefPubMed

45.

Arthurs G, Simpson J, Brown A, Kyaw O, Shyrier S, Concert CM (2015) The effectiveness of therapeutic patient education on adherence to oral anti-cancer medicines in adult cancer patients in ambulatory care settings: a systematic review. JBI Database System Rev Implement Rep 13:244–292PubMed

Titel: The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices
verfasst von: Teresa M. Salgado
Emily Mackler
Jane A. Severson
Jamie Lindsay
Peter Batra
Laura Petersen
Karen B. Farris
Publikationsdatum: 20.01.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 6/2017
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-017-3584-0

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States

Association between bone scan index and activities of daily living in patients with advanced non-small cell lung cancer

Characteristics of advanced cancer patients who were readmitted to an acute palliative/supportive care unit

A mindful self-compassion videoconference intervention for nationally recruited posttreatment young adult cancer survivors: feasibility, acceptability, and psychosocial outcomes

Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients

Comparison of integrative medicine centers in the USA and Germany: a mixed method study

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie